De-escalation of radiotherapy in HPV-negative non-nasopharyngeal head and neck squamous cell carcinoma: a systematic review.
Anja Dietze, Adam Zabini, Daniel H Schanne et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated de-escalation strategies in radiotherapy for HPV-negative non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC). The review identified 14 prospective studies, revealing low elective nodal failure rates (0-4.6%). However, randomized evidence for elective nodal dose reduction was mixed, indicating a need for further research.
Key findings
- Elective nodal failure rates were consistently low, ranging from 0% to 4.6%.
- Most recurrences occurred within high-dose volumes rather than de-escalated regions.
- Randomized evidence for elective nodal dose reduction showed mixed results, with some trials reducing toxicity but others halted for futility.
Why it matters
Understanding de-escalation strategies in HPV-negative HNSCC is crucial for minimizing treatment-related morbidity while maintaining effective tumor control, which can significantly impact patient quality of life.
What to keep in mind
The evidence is primarily derived from small, heterogeneous phase II studies with mixed HPV populations.